Unfortunately, President Obama appears intent on grinding pharmaceutical research to a halt. His proposed budget would slap price controls on prescription drugs, thereby depriving the sector of billions of dollars in revenue. That’s on top of the tens of billions in new taxes Obamacare assesses on the industry.
More money for the feds means less money for drug research and development. If pharmaceutical research falters, both patients and the economy will suffer.
Read the full article by Sally Pipes at Forbes.com.
More health reform information on the Obamacare page.